

Table E-1. Study characteristics for trials comparing hormone with placebo

Study	Country	Sites	Analyzed	Design	Study Arms	F/U (weeks)	Industry Funding	Editorial Assistance
Martin 1971	United States	2	165	RCT Plac Compare	3	12		No/NR
Campbell 1977	United Kingdom	1	136	Crossover	2	52		No/NR
Baumgardner 1978	United States	8	156	RCT Plac Compare	4	24		No/NR
Coope 1981	United Kingdom	1	55	Crossover	2	26		No/NR
Jensen 1983	Denmark	1	131	RCT Plac Compare	2	104		No/NR
Foidart 1991	Belgium	2	109	RCT Plac Compare	2	26		No/NR
Eriksen 1992	Denmark	NR	154	RCT Plac Compare	2	12		No/NR
Wiklund 1993	Sweden	15	223	RCT Plac Compare	2	12		No/NR
Derman 1995	United States	3	82	RCT Plac Compare	2	16	Yes	No/NR
Saletu 1995	Austria	1	64	RCT Plac Compare	2	12		No/NR
Good 1996	United States	NR	273	RCT Plac Compare	3	12		No/NR
Speroff (Study 1) 1996	United States	17	108	RCT Plac Compare	2	12	Yes	No/NR
Chung 1996	Hong Kong	1	83	Crossover	2	26		No/NR
Speroff (Study 2) 1996	United States	17	111	RCT Plac Compare	3	12	Yes	No/NR

Study	Country	Sites	Analyzed	Design	Study Arms	F/U (weeks)	Industry Funding	Editorial Assistance
Speroff (Study 3) 1996	United States	17	106	RCT Plac Compare	2	12	Yes	No/NR
Bacchi-Modena 1997	Italy	11	109	RCT Plac Compare	2	12		No/NR
Baerug 1998	Norway	5	119	RCT Plac Compare	3	12	Yes	No/NR
Bech 1998	Denmark	1	151	RCT Plac Compare	3	52		No/NR
de Vrijer 1999	Netherlands	16	254	RCT Plac Compare	3	12		No/NR
Leonetti 1999	United States	1	90	RCT Plac Compare	2	52	Yes	No/NR
Studd 1999	Multinational	63	355	RCT Plac Compare	5	12		No/NR
Polo-Kantola 1999	Finland	1	62	Crossover	2	12	Yes	No/NR
Casper 1999	Germany		67	RCT Plac Compare	2	24		No/NR
Cohen 1999	United States	Multi	259	RCT Plac Compare	2	12	Yes	No/NR
Rebar 2000	United States	25	204	RCT Plac Compare	2	104	Yes	No/NR
Speroff (Study 1) 2000	United States	11	219	RCT Plac Compare	5	16	Yes	No/NR
Rovati 2000	Italy	15	311	RCT Plac Compare	4	12	Yes	No/NR
Notelovitz 2000	United States	23	145	RCT Plac Compare	3	12		No/NR
Strickler 2000	United States	32	201	RCT Plac Compare	2	52	Yes	No/NR
Notelovitz 2000	United	15	333	RCT Plac	5	12	Yes	No/NR

Study	Country	Sites	Analyzed	Design	Study Arms	F/U (weeks)	Industry Funding	Editorial Assistance
	States			Compare				
DeAloysio 2000	Italy	1	156	RCT Plac Compare	3	12	Yes	No/NR
von Holst 2000	Germany	34	186	RCT Plac Compare	2	12		No/NR
Notelovitz 2000	United States	26	219	RCT Plac Compare	4	12	Yes	No/NR
Alexandersen 2000	Denmark	1	200	RCT Plac Compare	4	104	Yes	No/NR
Speroff (Study 2) 2000	United States	24	266	RCT Plac Compare	4	12	Yes	No/NR
Rigano 2001	Italy	1	362	RCT Plac Compare	2	26		No/NR
Utian (CEE alone arms) 2001	United States	57	117	RCT Plac Compare	4	52	Yes	No/NR
Simon 2001	United States	4	120	RCT Plac Compare	2	12	Yes	No/NR
Soares 2001	Brazil	2	50	RCT Plac Compare	2	12	Yes	No/NR
Utian (CEE/MPA arms) 2001	United States	57	152	RCT Plac Compare	5	52	Yes	No/NR
Rozenbaum 2002	France	21	165	RCT Plac Compare	3	12		No/NR
Shulman (Study 1) 2002	United States	32	293	RCT Plac Compare	3	12	Yes	No/NR
von Holst 2002	Germany	Multi	172	RCT Plac Compare	2	12		No/NR
Archer 2003	United States	11	221	RCT Plac Compare	3	12	Yes	No/NR
Vestergaard 2003	Denmark	Multi	1006	RCT Plac	2	260		No/NR

Study	Country	Sites	Analyzed	Design	Study Arms	F/U (weeks)	Industry Funding	Editorial Assistance
Speroff 2003	United States	35	333	Compare RCT Plac	3	13	Yes	No/NR
Jirapinyo 2003	Thailand	1	120	Compare RCT Plac	2	52	Yes	No/NR
Haines 2003	Hong Kong	1	152	Compare RCT Plac	3	52	Yes	No/NR
Hays 2003	United States		16608	Compare RCT Plac	2	52		No/NR
Gambacciani 2003	Italy	1	50	Compare RCT Plac	2	12		No/NR
Gelfand 2003	Canada	18	119	Compare RCT Plac	2	12	Yes	No/NR
Wren 2003	Australia	1	80	Compare RCT Plac	2	12	Yes	No/NR
Simunic 2003	Croatia	15	1612	Compare RCT Plac	2	52		No/NR
Parsons 2003	United States	16	94	Compare RCT Plac	2	13	Yes	No/NR
Berlex (SIP) 2003	United States	NR	180	Compare RCT Plac	2	12		No/NR
Rudolph 2004	Germany	2	129	Compare RCT Plac	2	24	Yes	No/NR
Yang 2004	Taiwan	1	51	Compare RCT Plac	2	24		No/NR
Schurmann 2004	Multinational	19	225	Compare RCT Plac	4	16		No/NR
Utian 2004	United States	Multi	281	Compare RCT Plac	4	12	Yes	No/NR
Dessole 2004	Italy	NR	88	RCT Plac	2	26		No/NR

Study	Country	Sites	Analyzed	Design	Study Arms	F/U (weeks)	Industry Funding	Editorial Assistance
				Compare				
Duramed (SIP) 2004	United States	NR	104	RCT Plac Compare	2	12		
Brunner 2005	United States		10739	RCT Plac Compare	2	52		No/NR
Onalan 2005	Turkey	1	210	RCT Plac Compare	3	52		No/NR
Bayer Healthcare (SIP) 2005	United States	NR	351	RCT Plac Compare	2	12		
Novartis (SIP) 2005	United States	NR	160	RCT Plac Compare	3	12		No/NR
Speroff (Study 1) 2006	United States	41	289	RCT Plac Compare	3	12	Yes	No/NR
Simon 2006	United States	37	200	RCT Plac Compare	2	12	Yes	No/NR
Nielsen 2006	Denmark	2	335	RCT Active Compare	3	104		No/NR
Osmanagaoglu 2006	Turkey	1	104	RCT Plac Compare	2	26		No/NR
Speroff (Study 2) 2006	United States	36	221	RCT Plac Compare	2	12	Yes	No/NR
Bachmann (d) 2007	United States	48	425	RCT Plac Compare	3	12	Yes	No/NR
Maki 2007	United States	19	180	RCT Plac Compare	2	17	Yes	No/NR
Endrikat 2007	Germany	31	324	RCT Plac Compare	2	12	Yes	No/NR
Lee 2007	South Korea	6	72	RCT Plac Compare	2	16	Yes	No/NR
Panay 2007	Multinational	Mult	575	RCT Plac	3	24	Yes	No/NR

Study	Country	Sites	Analyzed	Design	Study Arms	F/U (weeks)	Industry Funding	Editorial Assistance
Simon 2007	Multinational	28	484	Compare RCT Plac	4	12	Yes	Yes
Pefanco 2007	United States	1	57	Compare RCT Plac	2	156	Yes	No/NR
Bayer Healthcare (SIP) 2007	United States	NR	165	Compare RCT Plac	2	12		No/NR
Buster (Study 1) 2008	United States	43	151	Compare RCT Plac	2	12	Yes	No/NR
Veerus 2008	Estonia	3	796	Compare RCT Plac	2	187	Yes	No/NR
Davis 2008	Multinational	65	811	Compare RCT Plac	3	52	Yes	No/NR
Bachmann 2008	United States	9	230	Compare RCT Plac	3	12	Yes	No/NR
Welton 2008	Multinational	2	2130	Compare RCT Plac	2	52		No/NR
Buster (Study 2) 2008	United States	43	150	Compare RCT Plac	2	12	Yes	No/NR
Buster (Study 3) 2008	United States	43	153	Compare RCT Plac	2	12	Yes	No/NR
Simon (SIP) 2008	United States	42	248	Compare RCT Plac	2	12	Yes	No/NR
Benster 2009	United Kingdom	2	221	Compare RCT Plac	5	24	Yes	No/NR
Utian 2009	United States	43	318	Compare RCT Plac	3	12	Yes	Yes
Lobo 2009	Multinational	94	2974	Compare RCT Plac	3	104	Yes	No/NR
Haines 2009	Multinational	Mult	160	RCT Plac	2	12	Yes	Yes

Study	Country	Sites	Analyzed	Design	Study Arms	F/U (weeks)	Industry Funding	Editorial Assistance
		i		Compare				
Bachmann (d) 2009	United States	48	121	RCT Plac Compare	3	12	Yes	No/NR
Hedrick 2009	Multinational	48	495	RCT Plac Compare	4	12	Yes	No/NR
Baksu 2009	Turkey	1	132	RCT Plac Compare	4	52		No/NR
Bachmann (Study 1) 2009	Multinational	Mult i	215	RCT Plac Compare	2	12	Yes	No/NR
Freedman 2009	United States	88	275	RCT Plac Compare	2	12	Yes	No/NR
Gast 2009	Multinational	25	285	RCT Plac Compare	2	24	Yes	Yes
Bachmann (Study 2) 2009		Mult i	208	RCT Plac Compare	2	12	Yes	No/NR
Hassa 2010	Turkey	1	247	RCT Plac Compare	3	26		No/NR
Stevenson 2010	Multinational	15	313	RCT Plac Compare	3	13	Yes	No/NR
Bachmann 2010	United States	66	542	RCT Plac Compare	3	12	Yes	Yes
Raghunandan 2010	India	1	75	RCT Plac Compare	3	12		No/NR
Hedrick 2010	Multinational	48	488	RCT Plac Compare	4	12	Yes	No/NR
Liu 2011	Multinational	Mult i	1029	RCT Plac Compare	6	12		No/NR
Lin 2011	China	9	244	RCT Plac Compare	2	16	Yes	Yes
Demetrio 2011	Brazil	1	66	RCT Plac	2	24		No/NR

Study	Country	Sites	Analyzed	Design	Study Arms	F/U (weeks)	Industry Funding	Editorial Assistance
				Compare				
Liu 2012	United States	19	157	RCT Plac Compare	3	12	Yes	No/NR
Archer 2012	United States	78	351	RCT Plac Compare	3	12	Yes	Yes
Archer 2012	United States	78	344	RCT Plac Compare	3	12	Yes	No/NR
Cano 2012	Spain	12	167	RCT Plac Compare	2	12	Yes	No/NR
Polisseni 2013	Brazil	1	88	RCT Plac Compare	2	12	Yes	No/NR
Raz 2013	United States	8	59	RCT Plac Compare	2	192		No/NR
Archer 2013	United States	79	710	RCT Plac Compare	4	12	Yes	Yes
Pinkerton 2013	United States		410	RCT Plac Compare	4	52	Yes	No/NR

(a): data came from a conference abstract; (c): data came from posted results on the clinical trial registry; CEE: conjugated equine estrogen; (d): duplicate patient population with other included article; F/U: followup; (m): trial contains data from multiple publications; MPA: medroxyprogesterone acetate; Multi: multicenter trial; NR: not reported; Plac: placebo; RCT: randomized controlled trial; (SIP); data came from a package insert